Failure to Satisfy Listing Rule Form 8 K

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On August 19, 2024, Talis Biomedical Corporation (the "Company") filed with the Securities and Exchange Commission (the "SEC") the Company's quarterly report on Form 10-Q and disclosed that the Company had suspended all research and development activities as of June 30, 2024, anticipated commencing a voluntary petition under Chapter 11 of the United States Code and expected that the Company would be delisted from the Nasdaq Stock Market.

On August 22, 2024, the Company received a letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that based upon Nasdaq's review of the Company and pursuant to Nasdaq Listing Rule 5101 (the "Listing Rule"), Nasdaq believes that the Company is a "public shell," and that the continued listing of its common stock is no longer warranted. Nasdaq's notice also provided that, unless the Company timely appeals Nasdaq's determination, it would be subject to delisting.

While the Company does not believe that it currently meets the definition of a shell company as defined in Rule 12b-2 of the Exchange Act, given the suspension of all of its research and development activities as of June 30, 2024, it does not intend to petition Nasdaq for a hearing to appeal Nasdaq's determination. Accordingly, trading of the Company's common stock will be suspended at the opening of business on September 3, 2024, and a Form 25-NSE will be filed with the SEC, which will remove the Company's common stock from listing and registration on the Nasdaq Stock Market.